

REVIEW

Open Access

Predictive, preventive, personalised and participatory periodontology: 'the 5Ps age' has already started

Carlo Cafiero* and Sergio Matarasso

Abstract

An impressive progress in dentistry has been recorded in the last decades. In order to reconsider guidelines in dentistry, it is required to introduce new concepts of personalised patient treatments: the wave of predictive, preventive and personalised medicine is rapidly incoming in dentistry. Worldwide dentists have to make a big cultural effort in changing the actual 'reactive' therapeutic point of view, belonging to the last century, into a futuristic 'predictive' one. The first cause of tooth loss in industrialised world is periodontitis, a Gram-negative anaerobic infection whose pathogenesis is genetically determined and characterised by complex immune reactions. Chairside diagnostic tests based on saliva, gingival crevicular fluid and cell sampling are going to be routinely used by periodontists for a new approach to the diagnosis, monitoring, prognosis and management of periodontal patients. The futuristic '5Ps' (predictive, preventive, personalised and participatory periodontology) focuses on early integrated diagnosis (genetic, microbiology, host-derived biomarker detection) and on the active role of the patient in which networked patients will shift from being mere passengers to responsible drivers of their health. In this paper, we intend to propose five diagnostic levels (high-tech diagnostic tools, genetic susceptibility, bacterial infection, host response factors and tissue breakdown-derived products) to be evaluated with the intention to obtain a clear picture of the vulnerability of a single individual to periodontitis in order to organise patient stratification in different categories of risk. Lab-on-a-chip (LOC) technology may soon become an important part of efforts to improve worldwide periodontal health in developed nations as well as in the underserved communities, resource-poor areas and poor countries. The use of LOC devices for periodontal inspection will allow patients to be screened for periodontal diseases in settings other than the periodontist practice, such as at general practitioners, general dentists or dental hygienists. Personalised therapy tailored with respect to the particular medical reality of the specific stratified patient will be the ultimate target to be realised by the 5Ps approach. A long distance has to be covered to reach the above targets, but the pathway has already been clearly outlined.

Keywords: Predictive periodontology, Preventive periodontology, Personalised periodontology, Participatory periodontology, Lab-on-a-chip, Gas chromatographs, Cone beam computed tomography, Host-derived diagnostic markers, Saliva, Gingival crevicular fluid


* Correspondence: c.cafiero@unina.it
University of Naples "FEDERICO II", Naples 80131, Italy


Review

Introduction

Not too many years ago, the most frequent therapy in dentistry was tooth extraction: the teeth were pulled out and rapidly substituted by the application of a fixed or mobile prosthetic appliance. At that time, due to the weakness of the background in dental researches, just a small number of dentists were able to perform dental therapies on a specialised level. In the majority of cases, advanced therapies were generally considered not more than pioneeristic attempts. An impressive progress in dentistry has been recorded in the last decades. Synergic efforts (understanding of biological phenomena, new biomaterials, sophisticated surgical techniques, high tech in diagnostic tools, etc.) have carried dentistry away from the middle-aged situation described above (Figure 1), but this is not enough. In order to reconsider guidelines in dentistry, it is required to introduce new concepts of personalised patient treatments. On account of this, the current paper follows the recommendations of the recently published 'White Paper' of the European Association for Predictive, Preventive and Personalised Medicine (EPMA) [1,2]. The wave of predictive, preventive and personalised medicine is quickly incoming in dentistry. With regard to this, the mission of a specialised EPMA dental section will be to aid worldwide dentists make a big cultural effort in changing the actual 'reactive' therapeutic point of view, belonging to the last century, into a futuristic 'predictive' one (Figure 2). Enhancement in dental knowledge revealed genetic, microbiological and immunological mechanisms at the base of the most common dental diseases.

The first cause of tooth loss in industrialised world is periodontitis that strikes prevalently people older than 40 years of age. In consequence of this, the prevention of periodontitis is of capital importance to general and oral health since the European population is becoming progressively older (Figure 3). Periodontitis is a Gram-negative anaerobic infection whose pathogenesis is genetically determined and characterised by complex immune reactions to bacterial burden. It constitutes a very interesting model of chronic oral pathology, characterised by activity phases, related to many branches of medical researches such as genetic, microbiology and immunology. On account of this, chairside diagnostic tests based on saliva, gingival crevicular fluid and cell sampling are going to be routinely used by periodontists for a novel approach to the diagnosis, monitoring, prognosis and management of periodontal patients. As will be discussed later, genetic tests as well as the use of microbial analysis and the detection of biomarkers derived from host response will contribute to improve periodontal health. Predictive, preventive, personalised and participatory periodontology, the '5Ps', represents with no doubt the future of the profession of periodontology. A predictive approach due to the use of high-tech diagnostic tools will give us the possibility to detect patients at risk and to effect early diagnosis of periodontitis when it is easier to treat successfully. It will be organised as a personalised prevention, based upon the genetic and microbiological status of a single patient as well as personalised therapy tailored with respect to the particular medical reality of the specific patient. Finally, the active role of the patient will be emphasised through the introduction of participatory






periodontology, a concept in which networked patients will shift from being mere passengers to responsible drivers of their health.

The aim of this paper is to synthetically report actual information on the genetics, microbiology and immunology of periodontal disease related to biomarkers that can aid to have early diagnosis. Further biomarkers, coming out in the early destruction of periodontal tissues, will be equally reported and discussed. The present

article is directed not only to dental operators (such as general dentists, periodontists, dental hygienists) but also to medical doctors in order to enlarge the discussion group and to share our experiences and ideas with as much colleagues as possible. Considering the large number of professionals we intend to approach with the present paper, it seems clear that we have to discuss some basic topics about periodontal disease before introducing the specific periodontal biomarkers field.



Periodontal unit as a multi-functional complex

The periodontium is defined as an anatomic and functional complex which constitutes the supporting tissue of the teeth. Each of the periodontal components has its very specialised function. Periodontal tissues are distinct in the (1) gingiva and (2) deep periodontium (periodontal ligament, cementum and alveolar bone).

Gingiva

The gingiva is a coral pink tissue consisting of an epithelial layer and an underlying connective tissue. It is differentiated into marginal (free) gingiva and attached gingiva. The free gingiva extends at the vestibular and lingual/palatal aspects of the teeth and in the interdental space which constitutes the peak of interdental papillae. On the vestibular and lingual sides, the free gingiva extends from the gingival margin to the free gingival groove which marks the edge with the attached gingiva. The attached gingiva extends in the apical direction to the mucogingival junction where it becomes continuous with the alveolar mucosa [3] (Figure 4).

Deep periodontium

The deep periodontium is composed of the periodontal ligament, cementum and alveolar bone (Figure 5).

Periodontal ligament The periodontal ligament (alveolo-dental ligament) is a specialised connective tissue situated between the cementum covering the root of the tooth and the bone forming the socket wall. The extremities of collagen fibre bundles are embedded in the cementum (Sharpey's fibres) on one side and in the alveolar bone on the other side. It ranges in width from 0.15 to 0.38 mm.

Cementum The cementum is the hard, avascular connective tissue covering the roots of the teeth that serves primarily to attach the principal periodontal ligament fibres. There are two principal varieties of the cementum



Figure 4 Marginal (free) gingiva, attached gingiva and alveolar mucosa.




Figure 5 Deep periodontium. The main function of the deep periodontium is to support the teeth in their sockets and to act as a sensory receptor necessary for the proper positioning of the jaws and the proper pressure to be exercised during mastication.

classified on the basis of the presence or absence of cells: acellular extrinsic fibre cementum (primary cementum or acellular cementum) and cellular intrinsic fibre cementum (secondary cementum or cellular cementum). The acellular extrinsic fibre cementum extends from the cervical half to two thirds of the root. The high number of Sharpey's fibres inserting in it shows its fundamental function in tooth attachment. The cellular intrinsic fibre cementum is distributed along the apical third or half of the root and in furcation areas. It represents a reparative tissue.

Alveolar bone The mineralised bone is made up of lamellae (lamellar bone). It includes two types of bone tissue, the bone of the alveolar process and the alveolar bone lining the socket referred to as the alveolar bone proper or 'bundle bone' that consists of intrinsic fibre bundles running parallel to the socket. Embedded within this bundle bone and perpendicular to its surface are Sharpey's fibres. The alveolar bone is a clear example of a structure-function relationship because it increases in conjunction with the development of the teeth and it is partially lost in the absence of a tooth. In conclusion, the principal function of deep periodontal tissues is to support the teeth in their sockets. In addition, periodontal tissues act as a sensory receptor necessary for the proper positioning of the jaws and the proper pressure to be exercised during mastication. The peripheral feedback coming from the periodontal ligament gives signals to the muscles, ear and temporomandibular joints about



Figure 6 Upper jaw acute gingivitis in a non-smoker 26-year-old male patient. Abundant plaque deposit is visible on the surfaces of the teeth.

the quality of the food present under the teeth and, as a consequence, the information for the fine-tuning of masticatory pressure.

Periodontal diseases: the real infections of the oral cavity
Periodontal diseases are a cluster of inflammatory bacterial plaque-induced pathologies. At the end of the 1990s, a classification system for periodontal diseases was proposed, and it is currently used worldwide (see below) [4]:

1. Gingivitis
2. Chronic periodontitis
3. Aggressive periodontitis
4. Periodontitis as a manifestation of systemic disease
5. Necrotising ulcerative gingivitis/periodontitis
6. Abscesses of the periodontium
7. Combined periodontic-endodontic lesions

The most common periodontal diseases are gingivitis and periodontitis whose primary characteristics are synthetically reported below.

Gingivitis

Gingivitis is an inflammation of the periodontal marginal tissue (gingiva) in response to bacterial biofilms (bacterial plaque) adherent to tooth surfaces [5]. It is characterised by redness, bleeding, volume augmentation and diffuse



Figure 7 Lower jaw of the same patient. Calculus covers the entire surfaces of the teeth.



Figure 8 Upper jaw. Complete resolution of acute gingivitis and *restitutio ad integrum*.

pain (Figures 6, 7, 8, and 9). Gingivitis is a non-destructive periodontal disease in which no deep connective tissue destruction or bone resorption is detectable. In the presence of periodontal treatment, a complete resolution of the disease and *restitutio ad integrum* is to be expected.

Periodontitis

Periodontitis is a destructive pathology caused by Gram-negative facultative anaerobes affecting periodontal tissues (gingiva, cementum, periodontal ligament, alveolar bone). It causes periodontal breakdown (connective attachment loss, bone resorption and formation of periodontal pockets) as result of a complex bacteria-host response in genetically oriented patients (Figure 10). Periodontitis is characterised by a cyclic progression in which a recurrent active phase (periodontal breakdown) is followed by a quiescence phase. The natural history of the disease determines progressive periodontal destruction, tooth mobility and migration. This situation can lead to tooth loss and sometimes can render the patient edentulous. Therapy generally stops its progression and in some cases (regenerative surgery) can lead to *restitutio ad integrum*. Periodontitis is classified into chronic and aggressive forms.

Chronic periodontitis Chronic periodontitis (CP) affects up of 50% of the global population, especially older patients, but may occur in children too. In most cases, the rate of progression of chronic periodontitis is slow, and the amount of periodontal tissue destruction is



Figure 9 Lower jaw. The patient's compliance is of capital importance for a long-term result.




Figure 10 Periodontitis is a result of a complex bacteria-host response in genetically oriented patients. Co-factors such as diabetes and cigarette smoking are strongly associated with the aggravation of periodontitis.

generally commensurate with sub-gingival calculus and plaque amounts. CP is classified as *localised* when <30% of sites are affected and *generalised* when this level is exceeded (Figures 11 and 12).

Aggressive periodontitis Aggressive periodontitis (AP) is less common than the chronic form. In the primary dentition of 5–11-year-olds, the frequency ranges from 0.9% to 1.5% of subjects [6-8], and in the permanent dentition of 12–20-year-olds, the frequency ranges from 0.1% to 0.2% in Caucasian populations. AP generally affects younger patients causing rapid loss of attachment and bone destruction. The severity of periodontal tissue destruction is conflicting with the scarce amounts of microbial deposits. The reason of this destruction is the presence of elevated proportions of aggressive Gram-negative bacteria (*Aggregatibacter actinomycetemcomitans*



Figure 11 Generalised chronic periodontitis. The amount of periodontal tissue destruction commensurate with sub-gingival calculus and plaque amounts, diffuse pathological probing depth, mobility and migration are the main characteristics of this pathology.




Figure 12 Full-mouth series periapical X-rays show diffuse horizontal bone loss.


and *Porphyromonas gingivalis*), the phagocyte abnormalities and the hyperresponsive macrophage phenotype (elevated secretion of prostaglandin E2 (PGE2) and interleukin-1 (IL-1)) in response to bacterial lipopolysaccharides (LPSs). Aggressive periodontitis has been subclassified into localised and generalised forms [9,10].

Localised aggressive periodontitis Localised aggressive periodontitis (LAP) presents a circumpubertal onset. The first molar/incisor presents with interproximal attachment loss on at least two permanent teeth, one of which is the first molar, and involving no more than two teeth other than the first molars and incisors. Serum antibody response to infecting agents was detected in high quantity.

Generalised aggressive periodontitis Generalised aggressive periodontitis (GAP), formerly named generalised early-onset periodontitis, usually affects patients aged under 30. GAP is characterised by the presence of generalised interproximal attachment loss affecting at least three permanent teeth other than the first molars and incisors [11] (Figures 13 and 14).



Figure 13 Generalised aggressive periodontitis. The scarce amount of microbial deposits is conflicting with the severity of periodontal tissue destruction as shown in Figure 14.



The genetic bases of periodontitis

The observation that inheritance was an important component in the development of periodontal diseases was proposed as early as 1935 [12]. Investigations focused on genetic risk factors are currently characterising periodontal research in the genetic field.

Mutations and polymorphisms

DNA sequence variations are described as mutations and as polymorphisms. A mutation is defined as a change in a DNA sequence away from normal. In periodontitis, specific mutations have been identified to cause the genetic basis of various syndromic conditions (Table 1) [13]. Genetic mutations are deterministic of simple genetic diseases. However, these genetic diseases are rare and do not characterise the most common forms of periodontitis. In fact, from a genetical point of view, probably the most common forms of periodontitis arise as a result of single-nucleotide polymorphisms (SNPs). The arbitrary cut-off point between a mutation and a polymorphism is 1%. That is, to be classed as a polymorphism, the least common allele must have a frequency of 1% or more in the population. When the frequency is lower than this, the allele is regarded as a mutation. Numerous studies have investigated SNPs in both the chronic and aggressive forms

Table 1 Specific mutations cause the genetic basis of various syndromic conditions in which periodontitis is present

Disease	Biochemical/tissue defect	Inheritance
Papillon-Lefèvre syndrome	Cathepsin C	Autosomal recessive
Chédiak-Higashi syndrome	Lysosomal trafficking regulator gene	Autosomal recessive
Leukocyte adhesion deficiency type 1	Leukocyte chain adhesion molecule CD18	Autosomal recessive
Leukocyte adhesion deficiency type 2	Glucose diphosphatase-fucose transporter-1	Autosomal recessive
Cyclic neutropenia	Neutrophil elastase	Autosomal dominant
Haim-Munk syndrome	Cathepsin C	Autosomal recessive
Ehlers-Danlos syndrome	Collagen	Autosomal dominant

of periodontitis. The distribution of SNPs varied between ethnic groups. Ethnic difference(s) in genes encoding the interleukins IL-1 and IL-6, Fc receptors (Fc RIIa, Fc RIIIa and Fc RIIIb), tumour necrosis factor alpha (TNF- α), vitamin D receptor, CD14 and matrix metalloproteinase-1 (MMP-1) were found. Several studies investigated the genes affecting the expression of interleukin-1, interleukin-6, tumour necrosis factor, interleukin-10, E-selectins, Fc-gamma receptor, CD14, toll-like receptors and periodontal disease. The largest part of the studies shows no correlations between the presence of disease markers and the tested SNP in both the aggressive and chronic forms of periodontitis [14]. It is important to clarify that in complex disease, a given polymorphism is necessary but not sufficient to cause disease. In fact, the interplay of genetic and environmental factors is fundamental in determining the disease phenotype. Hence, a single functional genetic polymorphism is not sufficient to cause disease; consequently, such functional polymorphisms may be found in individuals with no evidence of disease.

Bacterial burden: a challenge for periodontal tissues

The average 200-lb (90 kg) human body carries around with it about 6 lb (2.7 kg) of bacteria. Some of them live in the oral cavity forming a huge source of bacteria: to give an idea, in 1 mm³ (1 mg) of dental plaque, 10⁸ bacteria are present. The Human Oral Microbiome

Table 2 Principal constituents of dental plaque

Constituents		
Bacterial aggregate	Gram-positive	
	Gram-negative	
Matrix of extracellular substance	Glucides	Levans
		Dextrans
		Glycogen
		Galactose
		Ribose
		Fucose
	Lipids	Glycolipids
		Phospholipids
Proteins	Triglycerides	
	Cholesterol	
	Glycoproteins	
	Glycosaminoglycans	
	Lipoproteins	
Ions and trace elements	Ca ⁺⁺ /PO ₄ ⁻	
	F ⁻	
	Ag, Mg, Co, Fe, Cu, Pb, Sn	

Table 3 The most frequent microbial species isolated in healthy gingiva, gingivitis and periodontitis

	Microbial species
Healthy gingiva	<i>Streptococcus oralis</i>
	<i>Streptococcus sanguis</i>
	<i>Streptococcus mitis</i>
	<i>Streptococcus gordonii</i>
	<i>Streptococcus mutans</i>
	<i>Streptococcus anginosus</i>
	<i>Streptococcus intermedius</i>
	<i>Gemella morbillorum</i>
	<i>Rothia dentocariosa</i>
	<i>Actinomyces naeslundii</i>
	<i>Actinomyces gerencseriae</i>
	<i>Actinomyces odontolyticus</i>
	<i>Peptostreptococcus micros</i>
	<i>Eubacterium nodatum</i>
	<i>Capnocytophaga ochracea</i>
	<i>Capnocytophaga gingivalis</i>
	<i>Campylobacter gracilis</i>
	<i>Fusobacterium nucleatum</i> subsp. <i>polymorphum</i>
	Gingivitis
<i>Streptococcus sanguis</i>	
<i>Streptococcus mitis</i>	
<i>Streptococcus intermedius</i>	
<i>Capnocytophaga ochracea</i>	
<i>Capnocytophaga gingivalis</i>	
<i>Campylobacter gracilis</i>	
<i>Prevotella loescheii</i>	
<i>Peptostreptococcus micros</i>	
<i>Eubacterium nodatum</i>	
<i>Actinomyces naeslundii</i>	
<i>Actinomyces israelii</i>	
<i>Campylobacter concisus</i>	
<i>Actinomyces odontolyticus</i>	
<i>Fusobacterium nucleatum</i> subsp. <i>nucleatum</i>	
<i>Eubacterium brachy</i>	
<i>Eikenella corrodens</i>	
<i>Aggregatibacter actinomycetemcomitans</i> serotype a	
Periodontitis	<i>Porphyromonas gingivalis</i>
	<i>Aggregatibacter actinomycetemcomitans</i> serotype b
	<i>Bacteroides forsythus</i>
	<i>PRO spirochete</i>
	<i>Treponema denticola</i>
	<i>Prevotella intermedia</i>
	<i>Prevotella nigrescens</i>
	<i>Campylobacter rectus</i>

Table 3 The most frequent microbial species isolated in healthy gingiva, gingivitis and periodontitis (Continued)

<i>Peptostreptococcus micros</i>
<i>Fusobacterium nucleatum</i> subsp. <i>vincentii</i>
<i>Fusobacterium nucleatum</i> subsp. <i>nucleatum</i>
<i>Selenomonas noxia</i>
<i>Selenomonas flueggeii</i>
Enteric species
<i>Fusobacterium alocis</i>
<i>Lactobacillus uli</i>
<i>Veillonella parvula</i>

Database lists 1,200 predominant oral species, with the order of 19,000 phylotypes [15].

Dental plaque is a biofilm containing over 700 individual taxa of aggregated microorganisms embedded within a self-produced matrix of extracellular substance composed of bacterial polymers and salivary and gingival exudate products (Table 2). The heterogeneity of plaque gradually increases and includes large numbers of Gram-negative anaerobic species in gingivitis (approximately 25%) and periodontitis (approximately 75%) as compared to healthy gingiva (approximately 13%) (Table 3).

Further and more recent studies have demonstrated that there are specific associations among bacterial species within dental plaque.

Five closely associated clusters have been reported (Figure 15):

1. The green cluster (*Campylobacter concisus*, *Eikenella corrodens*, *Actinobacillus actinomycetemcomitans* serotype a).
2. The yellow cluster made up of a group of streptococci (*Streptococcus mitis*, *Streptococcus sanguis*, *Streptococcus oralis*).
3. The purple cluster (*Actinomyces odontolyticus*, *Veillonella parvula*).
4. The red cluster (*P. gingivalis*, *Tanarella forsythia*, *Treponema denticola*).
5. The orange cluster (*Fusobacterium nucleatum* subspecies, *Prevotella intermedia*, *Prevotella nigrescens*, *Peptostreptococcus micros*, *Campylobacter rectus*, *Campylobacter showae*, *Campylobacter gracilis*, *Eubacterium nodatum*, *Streptococcus constellatus*, *Fusobacterium periodonticum*).

Finally, *Actinomyces naeslundii* genospecies 2 (*Actinomyces viscosus*), *Selenomonas noxia* and *A. actinomycetemcomitans* serotype b did not cluster with other species [16].

Periodontopathogens also colonise non-dental surfaces such as the tongue dorsum, oral mucosa and tonsils, and for this reason, periodontitis therapeutic measures have




Figure 15 Specific associations among bacterial species within dental plaque characterise five closely associated clusters. (Adapted from [16]).

to eliminate periodontal pathogens in the whole mouth (Figure 16) [17].

An epidemiologic study found out that close members of the same family were infected via saliva with *A. actinomycetemcomitans* strains of the same biotype and serotype [18]. For this reason, prevention measures against periodontal pathogens must include the entire family members in order to prevent cross-infection [19].

Even if there are no sufficient microbiological evidences that could help us distinguish the different forms of periodontitis, it is clear that:

1. The chronic and aggressive forms of periodontitis are not monoinfections.
2. Some microbiota are more important than others as aetiological agents of periodontitis.

Periodontal tissues as a ‘battlefield’ in the struggle against oral bacteria

The host-microbial balance constitutes the situation in clinically healthy periodontal tissue. Plaque accumulation and immunitary response can create an imbalance



Figure 16 Tongue dorsum brushing with 0.5% chlorhexidine gel. The red colour of the tongue is due to the use of erythrosine pads that have the capability to reveal the presence of bacterial plaque on the teeth and soft tissue. Chlorhexidine (0.12%) puffs on the tonsils and chlorhexidine (0.12%) mouth rinse are further procedures necessary to eradicate periodontal pathogens from the whole mouth.

of the host-parasite relationship occurring in destructive periodontal lesion. In fact, the fight among bacteria and immunocompetent cells can devastate the battlefield, that is, the periodontium.

For simplification, we arbitrarily divided the immunitary response in periodontal tissue into three different compartments (epithelium, connective, bone) in which three main cells (polymorphonuclear neutrophils (PMNs),




Figure 17 The mortal fight among bacteria and immunocompetent cells. It can devastate the 'periodontal battlefield' since defensive immunitary reaction could paradoxically contribute to the tissue destruction. Activated polymorphonuclear leukocytes, indeed, can cause tissue damage as a result of a variety of enzymes and oxygen metabolites that are released from their granules during the battle against microbes. Bacterial LPSs activate macrophages, lymphocytes and fibroblasts which secrete lymphokines activating MMPs. Metalloproteinases are enzymes that degrade the connective extracellular matrix and can be detected in gingival crevicular fluid. Finally, many substances (PGE2, IL-1, IL-6, TNF- α) secreted by M ϕ , fibroblasts, plasma cells and T lymphocytes are primarily involved in osteoclastic activation via the RANKL-OPG expression system.

macrophages, osteoclasts) are representative of three different topical moments (Figure 17).

Epithelial compartment: PMN activation

PMN leukocytes represent the first line of defence forming a protective wall against microorganisms. Activated polymorphonuclear leukocytes can cause tissue damage as a result of their accumulation in epithelial tissues. Further damages can be caused by a variety of enzymes and oxygen metabolites that are released from their granules during the battle against microbes [20,21]. Oxygen metabolites such as hydrogen peroxide (H_2O_2) and reactive oxygen radicals (OH^-) that are released into the phagosome defensive immunitary reaction could paradoxically contribute to the tissue destruction. As a consequence, the junctional epithelium becomes filled with ulcers and allows the passage of bacteria and their products in the underneath connective tissue.

Connective compartment: macrophage activation

In the subsequent line of defence, macrophages ($M\phi$) play a decisive role to restrict bacterial spreading in the connective tissue. Macrophages are an important source of lysosomal enzymes, cytokines and inflammatory mediators such as IL-1, TNF- α , PGE2 and transforming growth factor beta (TGF- β).

IL-1 is the principal inflammatory mediator released by LPS-activated macrophages, lymphocytes and fibroblasts. IL-1 stimulates $M\phi$ and fibroblasts to secrete

PGE2; moreover, it causes osteoclastic differentiation and activation [22].

TNF- α , principally secreted by LPS-stimulated macrophages and lymphocytes, causes osteoclastic differentiation and activation [23].

PGE2 causes vasodilatation, vasopermeability and resorption of the alveolar bone. IL-1, TNF- α and PGE2 stimulate fibroblasts and $M\phi$ to release MMPs, urokinase plasminogen activator (u-PA), tissue inhibitor of metalloproteinases, PGE2, TGF- β and interleukin-1 receptor antagonist. As described below, disease severity appears linked to the existent equilibrium among different involved molecules. The u-PA causes plasminogen transformation in plasmin which activates MMPs, enzymes degrading the connective extracellular matrix. They can be detected in gingival crevicular fluid, particularly during the activity phase [24].

Bone compartment: osteoclast activation

Inflammation progresses in the apical direction involving the bone tissue. It is important here to highlight that bacterial plaque never gets in direct contact with the bone tissue and that 'running away' from the bacterial aggregate is always at least 2 mm in distance from it. Many substances (PGE2, IL-1, IL-6, TNF- α) secreted by $M\phi$, fibroblasts, plasma cells and T lymphocytes are primarily involved in osteoclastic activation.

The receptor activator of NF- κ B ligand (RANKL) is a recently described member of the tumour necrosis




Figure 18 The RANKL-OPG expression system. Under physiological condition, RANKL produced by osteoblasts binds to RANK on the surface of osteoclast precursors. OPG is produced by fibroblasts constituting a false target for RANKL. The balanced regulation of the RANKL-OPG expression system can determine health from disease.

factor superfamily promoting osteoclastic differentiation from haemopoietic precursors and the inhibition of osteoclast apoptosis. Under physiological condition, RANKL produced by osteoblasts binds to RANK on the surface of osteoclast precursors. RANKL is up-regulated by osteotropic factors such as PTH and IL-11. Osteoprotegerin (OPG), a member of the TNF receptor superfamily, is produced by fibroblasts constituting a false target for RANKL [25,26]. Hence, OPG is an inhibitor of bone resorption. The balanced regulation of the RANKL-OPG expression system can determine health from disease (Figure 18).

Environmental risk factors

Smoking and diabetes mellitus are the most frequent co-factors strongly associated with the aggravation of periodontitis. Other situations such as obesity, stress and osteoporosis have been identified as co-factors in the progression of periodontitis [27].

Diabetes mellitus

The present percentage of diabetics is very high worldwide, and these numbers are increasing dramatically. It is not exaggerate to claim that we are going to face a dramatic diabetic emergency in the next years (Figure 19).

The contemporary consensus is that diabetic patients are at increased risk of periodontitis [29]. Patients with type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus have been found to be equally at risk for periodontitis [30]. The severity of periodontitis has been proved to increase with the onset of diabetes at a younger age as well as with poorer metabolic control of diabetes [31]. It has been claimed that periodontitis is the sixth complication of diabetes, together with retinopathy, nephropathy, neuropathy, macrovascular diseases and altered wound healing [32]. Diabetes mellitus is the only systemic disease positively associated with attachment loss with an odds ratio of 2.32 (95% confidence interval (CI) 1.17–4.60) [33]. Some authors presumed a two-way relationship in which




Figure 19 More than 371 million people have diabetes worldwide and the number is increasing in every country. It is important to highlight that half of the people with diabetes do not know that they have it, and for this reason, the majority of people who die from diabetes are under the age of 60. Nearly 5 million people died and US\$471 billion were spent due to diabetes in 2012. International organisations are going to face a dramatic diabetic emergency in the next years. (Adapted from [28]).

periodontal therapy can improve metabolic control in diabetic patients [34]. In these studies, periodontal treatment was associated with a reduction in HbA1c levels, and moreover, inflammatory biomarkers decline with periodontal treatment [35-37]. In contrast, non-significant reduction in HbA1c values was recorded in several studies [38-40]. Very recently, a meta-analysis of nine intervention studies of 485 people with diabetes concluded that periodontal treatment could lead to a significant 0.79% (95% CI 0.19–1.40) reduction in HbA1c levels [41]. A recent Cochrane review on the treatment of periodontal disease for glycaemic control in people with diabetes declared that further controlled studies are necessary to clarify the topic [42]. These conflicting data are difficult to understand in order to clarify the influence of periodontitis in glycaemic control. Hence, supplementary controlled clinical trials appear urgent and necessary to definitely assess if periodontal therapy can improve metabolic control in diabetic patients.

Smoking

Over the past decades, a multitude of papers about the relationship between smoking and periodontitis have been published. The contemporary consensus is that:

1. Cigarette smoking is associated with a relative risk, ranging from 2.05 (95% CI 1.47–2.87) for light smokers increasing to 4.75 (95% CI 3.28–6.91) for heavy smokers, of developing periodontitis [33,43].
2. The negative effect of smoking is dose dependent and cumulative [44].
3. The negative effect of smoking is marked in younger individuals [45].
4. Smoking affects the healing potential of periodontal tissues [46].
5. Smoking is associated with the recurrence of periodontitis during periodontal maintenance [47].

Obesity, stress and osteoporosis

Other conditions such as obesity, stress and osteoporosis have been involved as co-factors in the progression of periodontitis, even if the association appears weak and still debatable.

Obesity It has been suggested that obesity is a strong risk factor for periodontal tissue destruction [48] since adipose tissue represents much more than a fat accumulation. It produces cytokines and hormones, collectively called adipokines or adipocytokines, which may play a key role in modulating periodontitis [49].

An association between obesity and periodontal disease in humans was reported for the first time by Saito et al. [50]. The authors estimated that the relative risk

for periodontitis was 3.4 in persons with a body mass index of 25–29.9 kg/m² and 8.6 in those with a body mass index of >30 kg/m². These results were confirmed by other authors [51,52]. Genco et al. [53] demonstrated that the severity of periodontal attachment loss was modulated by insulin resistance. In addition, it was reported that maintaining a normal weight was associated with a poorer frequency of periodontitis [54,55].

Stress The impact of stress on periodontal diseases has not yet been clarified. Stressful life events have been shown to modulate the endocrine and immune systems. Stressful life events could affect periodontal disease progression through (1) unhealthy behaviours (poor oral hygiene, increased tobacco smoking) and (2) pathophysiological factors (higher glucocorticoid and catecholamine levels) which affect bacterial, immunological, inflammatory and hormonal profiles, leading to an increased susceptibility to periodontal disease [56,57]. Finally, in a systematic review, a positive relationship between stress and chronic periodontitis was confirmed [58].

Osteoporosis Osteoporosis is a metabolic bone disorder characterised by the loss of bone mineral density, principally recorded in postmenopausal women. It has been proposed that osteoporosis could affect the alveolar bone leading to rapid resorption in periodontal women. In one study, 189 postmenopausal women were controlled over a 7-year period. An association between the loss of bone mineral density and increased risk of additional tooth loss was reported. In a review, it has been shown that 7 out of 17 studies reported a positive relationship between osteoporosis and clinical attachment loss. Eleven out of 19 studies found a positive association between osteoporosis and tooth loss [59]. Other studies showed negative or equivocal results [60].

It can therefore be concluded that since many of the studies were uncontrolled and had small sample sizes, the validity of their conclusions needs to be confirmed. Thus, the association between osteoporosis and periodontitis in humans remains weak and still debatable [61].

Periodontology approaches the future: 5Ps for five diagnostic levels

In addition to the traditional instruments for periodontal diagnosis, in the next future, well-organised population screening protocols utilising chairside diagnostic biomarkers for periodontal disease will be disposable. With reference to this, the last section of the present paper will be focusing on the diagnostic tools currently utilised for periodontal diagnosis (*the present time*) and on the most promising diagnostic tools (i.e. biomarkers and



Figure 20 Full-mouth high-definition digital photographs. By the use of a high-resolution professional digital camera, the operator takes a series of pictures during the initial visit. Before and after pictures can give periodontists and patients an objective representation of periodontal health improvement. Thus, the camera is a fantastic educational aid to reinforce the compliance of the patients and a diagnostic tool for the periodontist.

high-tech instrumentations) that are going to enter in clinical periodontology (*the next future*).

The present time: a precise picture of a single periodontal patient's existing condition

Diagnostic imaging and periodontal charting provide a complete description of the patient's periodontal condition.

Diagnostic imaging: a fundamental step to assess the periodontal conditions of a single patient

Full-mouth high-definition digital photographs By the use of a high-resolution professional digital camera, the operator takes a series of five pictures (frontal, right lateral, left lateral, palatal and lingual sides) during the initial visit. Since the camera is used in tandem with a computer screen, we can, in real time, easily show the patient the recorded images to illustrate his/her dental and periodontal health. The camera is not only a diagnostic tool but also a fantastic educational aid in helping us to reinforce the *compliance* of the patients, one of the most important topics in participatory periodontology. Finally, 'before and after' pictures can give periodontists and patients an objective representation of periodontal health improvement (Figure 20).

Full-mouth series periapical X-rays An intra-oral X-ray provides a clear picture of the state of the patient's individual tooth from the crown to the tip of its root (Figure 21). Moreover, it provides information on the

height and configuration of the interproximal alveolar bone. A full-mouth X-ray series is an important diagnostic support in periodontal patients (14/16 periapical X-rays). Full-mouth series periapical X-rays create a full view of the patient's teeth and surrounding bone tissue which must be combined with a meticulous assessment of periodontal charting in order to make a correct evaluation regarding 'horizontal' and 'angular' bony defects.

Periodontal charting: a complete status of the patient's periodontal health

Periodontal charting (full-mouth plaque score, full-mouth bleeding score, probing depth, clinical attachment level, bleeding on probing, recessions, mobility, migration, halitosis) provides a complete picture of periodontal conditions of a single patient (Figure 22) [3]. Measurements are accomplished with a calibrated periodontal probe (Figure 23) inserted into the sulcus and in a parallel position with respect to the long axis of the tooth (Figure 24).

Full-mouth plaque score The full-mouth plaque score is defined as the percentage of sites where plaque is present divided by the number of sites examined.

Full-mouth bleeding score The full-mouth bleeding score is defined as the percentage of sites bleeding with respect to the number of sites examined.




Figure 21 A full-mouth X-ray series. It is an important diagnostic support in periodontal patients (14/16 periapical X-rays) since it creates a full view of the patient's teeth and surrounding bone tissue.




Figure 22 Periodontal charting provides a complete picture of the periodontal conditions of a single patient. (Adapted from [62]).

Probing pocket depth Probing pocket depth (PPD) is the distance from the gingival margin to the bottom of the gingival sulcus/pocket. It is measured by means of a graduated periodontal probe with a standardised tip diameter of 0.5 mm. Measurement is taken for each tooth at the mesio-buccal line angle, the mid-buccal, the distobuccal line angle, the distolingual line angle, the mid-lingual and the mesio-lingual line (six sites for each

tooth) (Figures 25 and 26). The physiological value of PPD is considered to be ≤ 3 mm. PPD allows an immediate evaluation of diseased sites.

Clinical attachment level Clinical attachment level (CAL), formerly called probing attachment level, is assessed by means of a graduated probe and expressed as the distance in millimetres from the cement-enamel




Figure 23 Calibrated periodontal probes are routinely used for periodontal screening.

junction (CEJ) to the bottom of the periodontal pocket (Figures 25 and 26). The severity of the attachment loss may be considered mild (CAL = 1–2 mm), moderate (CAL = 3–4 mm) or severe (CAL \geq 5 mm).

Recessions Recession (REC) is defined as the apical migration of the gingival margin. In most cases, it is due to gingival inflammation or incorrect (traumatic) tooth brushing. It is measured from the cement-enamel junction to the gingival margin by the use of a periodontal probe (Figure 26).

Bleeding on probing A periodontal probe is inserted at the 'bottom' of the gingival sulcus or periodontal pocket. Blood coming out from the bottom of the pocket can be recorded during probing (Figure 27). Bleeding on probing (BoP) is currently the unique predictive test routinely used for monitoring disease progression or periodontal stability (discussed in the next sections).

Mobility and migration Unphysiological mobility and migration are generally due to the reduction of periodontal support caused by bone resorption in consequence of periodontitis. Physiological forces (tongue, lips, occlusion, etc.) can cause the movement and migration of the tooth with reduced periodontium.

Halitosis Halitosis is defined as the presence of unpleasant breath odour. Gram-negative bacteria are the primary pathogens responsible for oral malodour production. Other causes of halitosis are uncontrolled diabetes, gastrointestinal diseases, renal failure and diseases affecting the upper/lower respiratory tract.

Unfortunately, periodontists can get only few predictive information about the progression and none about

the rise of the disease from the tools described above. BoP is currently the unique predictive test used by periodontists for routinely monitoring disease progression or periodontal stability. BoP repeatedly positive (BoP+) is a predictor of future loss of attachment (activity phase) in 30% of cases (positive predictive value), meanwhile BoP repeatedly negative (BoP-) is a predictor of periodontal health in 98% of cases (negative predictive value) [63-65]. In addition to that, a functional diagram to evaluate the patient's risk for recurrence of periodontitis ('spider's web') has been proposed (Figure 28). It consists of an assessment of the level of infection (full-mouth bleeding score), the prevalence of residual periodontal pockets, tooth loss, an estimation of the loss of periodontal support in relation to the patient's age, an evaluation of the systemic conditions of the patient and finally an evaluation of environmental and behavioural factors such as smoking. All these factors should be contemplated and evaluated together [66]. Bearing in mind what has been discussed above, it appears clear that, at present, a periodontal defence strategy is almost totally reactive: periodontists take action generally when periodontitis has already begun in periodontium destruction. In order to face mild or advanced periodontal lesions, periodontists are currently able to put in place sophisticated periodontal therapeutic strategies, but this does not seem enough. Recently, researches are gradually giving us the instruments to switch the therapeutic point of view from the current reactive to a more advanced predictive model (Figure 29).

The next future: hi-tech diagnostic tools and specific biomarkers to detect early periodontal damage

Knowledge in dentistry is estimated to double every 4–5 years in comparison with the 1950s when it was estimated to take 25 years for such an expansion [68].



Figure 24 A periodontal probe. It is inserted into the sulcus and in a parallel position with respect to the long axis of the tooth. The physiological value of PPD is considered to be \leq 3 mm. PPD allows an immediate evaluation of diseased sites.



Figure 25 PPD and CAL measurements. They are taken for each tooth at (left to right) the mesio-buccal line angle, the mid-buccal, the distobuccal line angle, the distolingual line angle, the mid-lingual and the mesio-lingual line.




Figure 26 PPD, CAL and REC measurements. PPD (blue line) is the distance from the gingival margin to the bottom of the gingival sulcus/pocket. CAL (green line) is assessed by means of a graduated probe and expressed as the distance in millimetres from the CEJ to the bottom of the periodontal pocket. REC (orange line) is defined as the apical migration of the gingival margin. It is measured from the cement-enamel junction (curved yellow green line) to the gingival margin.

Enhancement in dental knowledge revealed genetic, microbiological and immunological mechanisms at the base of periodontal diseases. Point-of-care (POC) testing allows rapid diagnostic tests in which results can be obtained immediately rather than waiting days for outside lab results to arrive [69]. Chairside tests (CSTs) belong to POC cluster of analysis. They can give an



Figure 27 Blood coming out from the bottom of the pocket can be recorded during probing (BoP+).




Figure 28 Spider's web. It consists of an assessment of the level of infection of a single patient contemplated and evaluated together. In the present case, a heavy-smoker 50-year-old patient presents a high periodontal risk (30 BOP + sites, 32 sites with PPD \geq 5 mm). (Adapted from [67]).




Figure 29 The aim of predictive, preventive, personalised, participatory periodontology. The aim is to transform the actual reactive therapeutic point of view, in which tissues destruction is clinically detectable, into a futuristic predictive one in which the disease is early intercepted when it is already in a sub-clinical phase.

immediate indication on the dental health of a single patient to dental operators. CSTs based on saliva, gingival crevicular fluid, cell and bacteria sampling are going to be routinely used by periodontists for a novel approach to the diagnosis, monitoring, prognosis and management of periodontal patients. In the larger healthcare community, 'dentists and oral health professionals may be positioned to expand the reach and impact of preventive medicine through the application of cost-effective and non-invasive oral fluid screening tests and referring patients for necessary medical care' [70].

The first cause of tooth loss in industrialised world is periodontitis which is the result of the interaction between genetic tendency and environment influence. In order to understand the growing value of *the 5Ps*, we have to consider some data that are currently arising:

1. The European population is becoming progressively older.
2. Periodontitis generally strikes people older than 40 years.
3. Periodontitis can cause serious detriment of the stomatognathic organ.

It appears clear, therefore, that periodontitis has to be considered as a social disease since it affects millions of people in Europe, and consequently, strategies have to be organised by national and international health organisations in order to intercept and treat the disease before it

can create serious damages to a large part of the European population. A similar situation has been recorded in the USA in which 31% of the population exhibited mild forms of periodontitis, 13% displayed periodontitis of moderate severity and 4% suffered from advanced periodontitis [71]. In order to face this situation, we should modify our approach towards diseases. Today, the work of periodontists is considered as 'a reactive effort' in the sense that we wait until the patient is sick before responding; on the contrary, the futuristic 5Ps focuses on the early integrated diagnosis (genetic, microbiology, host-derived biomarker detection) with the intention to detect periodontitis at an earlier stage, when it is easier to be treated successfully.

Here, we intend to propose five diagnostic levels (high-tech diagnostic tools, genetic susceptibility, bacterial infection, host response factors and tissue breakdown-derived products) to be evaluated with the intention to obtain a clear picture of the vulnerability of a single individual to periodontitis in order to organise patient stratification in different categories of risk (Figure 30).

First diagnostic level: (lab-on-a-chip, gas chromatographs, cone beam computed tomography) High-tech diagnostic tools will give periodontists the possibility:

1. To identify a periodontal initial lesion when it is not yet clinically detectable.
2. To intercept the so called 'active phase' of periodontitis.




Figure 30 5Ps flow chart. Five levels characterise a futuristic approach for periodontal diagnosis. The first level is represented by high-tech diagnostic tools such as LOC and CBCT. In the next future, LOC will be able to give us genetic, microbiological and host-derived information in real time. Co-factors (e.g. diabetes, osteoporosis) will be detected by the use of dedicated high-tech chairside diagnostic tools. Moreover, a detailed bone tissue morphology is revealed by low-radiation digital computed tomography which offers a digital volume composed of three-dimensional voxels that can then be manipulated with specialised software. The second level will provide useful information about the genetic susceptibility of a single patient, while the third level will give us the presence of causative bacterial factors in dental plaque. Finally, host-derived biomarkers (host response factors and factors derived from periodontal tissue breakdown) will be chairside-detected in order to early intercept periodontal destruction.

Lab-on-a-chip prototypes, gas chromatographs and cone beam computed tomography are three categories of high-tech devices that will be used everyday for the diagnosis of periodontitis in the not too distant future.

Lab-on-a-chip A lab-on-a-chip (LOC) is a device that integrates several laboratory functions on a single chip of only millimetres in size (Figures 31 and 32).

LOCs deal with the handling of extremely small fluid volumes down to less than picolitres (microfluidics). Microfluidics represent the technology behind a new miniaturised analysis system for biological applications such as DNA amplification, purification and separation [72]; sequencing [73]; proteomic analysis [74]; and single-cell gene expression profiling [75]. The use of microfluidic devices has a number of significant advantages such as smaller sample requirement (usually several nanolitres), reagents come with the chip and reduced reagent consumption (especially significant for expensive reagents, which is an important concern in clinical laboratories today) that means an immediate indication on the periodontal health of a single patient to dental operators [76]. Finally, the fabrication techniques used to construct microfluidic devices are relatively inexpensive and very open to mass production.

Gas chromatographs Halitosis is a major concern to the general public and the source of a multi-million-dollar industry worldwide [77]. Many patients affected by oral malodour often remain completely unaware of this fact, while others complain of halitosis even if no objective basis can be found: this situation has been defined as the 'bad breath paradox'. Halitosis is caused by physiologic or pathologic conditions. Physiologic halitosis (the so-called 'morning breath') is caused by the



Figure 31 Lab-on-a-chip micronised pulse oximeter. Until a few years ago, the diagnostic tool shown in the picture was sensibly bigger than the current one, and for this reason, it could be used only in hospitals. Nowadays, thanks to the reduced dimensions, the oximeter can be lent from hospitals to patients, who can so check daily their oxygen absorption in their own houses.



Figure 32 Probably the first chairside lab-on-a-chip utilised was the illustrated tool to check glycaemic level. This instrument can be useful for initial diabetes screening in patients at risk. By the use of the patient's single blood drop, the operator can inspect, in a few minutes, the actual glycaemic level in the patient's blood.

stagnation of saliva that disappears with drinking, consumption of food or tooth brushing.

Pathologic halitosis is principally caused by volatile sulphur compounds (VSCs), a family of catabolites resulting from oral bacterial activity. The most important determinants of malodour are hydrogen sulphide (H_2S) and methyl mercaptan (CH_3SH), which are catabolites of cysteine and methionine. Other volatile components are aromatic compounds resulting from the degradation of tryptophan (indole and skatole), short-chain fatty acids (acetic and propionic) and some polyamines (cadaverine and putrescine) (Table 4) [78]. The production of volatile sulphureous compounds is mainly derived by the putrefaction of food debris, cells, saliva and blood within the oral cavity mainly through microbial activity [79]. The intensity of clinical bad breath is significantly associated with the amount of intra-oral VSCs [80]. Gram-negative bacteria are the primary pathogens responsible for oral malodour production [81]. Patients with periodontal diseases often complain of oral malodour since the periodontal pocket is an ideal

Table 4 Principal volatile components responsible for oral pathologic halitosis

Volatile components	Compounds
Volatile sulphur compounds	Hydrogen sulphide, methyl mercaptan
Aromatic compounds	Indole, skatole
Short-chain fatty acids	Acetic, propionic
Polyamines	Cadaverine, putrescine

environment for VSC production with respect to the bacterial profile and sulphur source. Other authors demonstrated that a higher amount of VSCs was highly correlated with probing pocket depth, clinical attachment level, bleeding on probing, radiographic bone loss and Gram-negative pathogen species (*T. denticola*, *P. gingivalis*, *P. intermedia*) [82]. The most common device used to evaluate halitosis is the Halimeter® (Interscan Corp., Chatsworth, CA, USA) that measures volatile sulphur compounds in exhaled air. The Halimeter® does not measure other important odorants, such as volatile fatty acids and cadaverine, which are involved in oral halitosis: this could lead to a false negative result when malodour can be detected by the examiner, but the volatile sulphur compound levels are in the low range [83]. A portable gas chromatograph named Oral Chroma™ (Abilit Corp., Osaka, Japan) has been introduced to detect VSCs [84].

The Halimeter® has been shown to be more sensitive to H₂S than to methyl mercaptan and almost insensitive to dimethyl sulphide, whereas the Oral Chroma™ measures all three gases with equally high sensitivities [85].

Cone beam computed tomography Multi-slice computed tomography (MSCT) is a medical imaging technique using a narrow fan beam that rotates around the patient's head acquiring thin axial slices. During these repeated rotations, MSCT emits a high radiation dose, and it leaves a gap of information between each rotation. Consequently, the software must connect together the images and calculate what is missing. Cone beam computed tomography (CBCT) technology was first introduced in the European market in 1996 and into the US market in 2001 [86]. CBCT uses a cone-shaped beam (the X-rays are divergent) to acquire the entire image in a scan using only one rotation. During a CBCT scan, the scanner rotates around the patient, obtaining up to almost 600 separate images. The scanning software collects the anatomical data and produces a digital volume composed of three-dimensional voxels (instead of traditional pixels) that can then be visualised and manipulated with specialised software. The result is a more precise image without missing information (Figure 33).

Second diagnostic level: genetic susceptibility The largest part of the studies shows no correlations between the presence of disease markers and the tested SNPs in both the aggressive and chronic forms of periodontitis [14]. The polymorphisms that seemed to be linked with periodontitis in different ethnic groups were associated with the Fc-gamma receptor genes. However, these polymorphisms of the same gene were found in both chronic periodontitis and aggressive periodontitis [87,88]. A weak association between the SNP in interleukin-1 genes and

chronic periodontitis was found in a recent meta-analysis [89]. Interleukin-1 is a pro-inflammatory agent that is released by macrophages, lymphocytes, platelets and endothelial cells. The gene encoding this cytokine is assigned to chromosome 2q13–21 [90].


In 1997, Kornman et al. described a composite genotype formed by two polymorphic loci - interleukin-1A (-889) and interleukin-1B (+3954) - which are single-nucleotide polymorphisms that carry a C-T transition [91]. Interleukin-1A (-889), however, was outdated by the investigation of the interleukin-1A (+4845) G-T dimorphism, in which the two loci comprising the periodontitis-associated genotype were found to be in linkage disequilibrium [92].

Therefore, the analysis of the interleukin-1A (+4845) single-nucleotide polymorphism provides the same genetic information [93]. Several studies have evaluated the utility of the commercially available IL-1 genetic susceptibility test (Figure 34) [94]. Unfortunately, we do not have any sufficient size-controlled studies that would allow us to evaluate the efficacy of the IL-1 genotype [95,96]. Thus, although certain studies are encouraging, there are currently insufficient data to support a modification of treatment protocols for chronic periodontitis patients based on IL-1 testing [97].

Third diagnostic level: bacterial infection Haffajee and Socransky [98] suggested six types of lines of evidence to be used to support an aetiological role for bacteria in periodontal infections:

1. Elevated odds ratio in disease.
2. Conversion of disease to health when bacteria are suppressed.
3. Development of a host response.
4. Presence of virulence factors (capability to avoid host defences and to damage tissues).
5. Evidence from animal studies corroborating the observations in humans.
6. Support from risk assessment studies.

Following the above criteria, the consensus report of the World Workshop on Periodontitis [99] identified three bacterial species for which sufficient data have accumulated as *causative factors* for periodontitis: *A. actinomycetemcomitans* (recently renamed to *Aggregatibacter actinomycetemcomitans*) [100], *P. gingivalis* and *Bacteroides forsythus* (renamed to *Tannerella forsythia*) [101]. The consensus report stated that *A. actinomycetemcomitans* is most often found in aggressive ('early-onset') periodontitis, whereas *P. gingivalis* and *T. forsythia* are found more frequently in chronic ('adult-onset') periodontitis. *Moderate evidence* to support an aetiological role was reported for *C. rectus*, *E. nodatum*, *P. intermedia*,



P. nigrescens, *Parvimonas micra* (formerly *Micromonas micros* and *Peptostreptococcus micros*), the *Streptococcus intermedius* complex and *T. denticola*. Finally, an initial evidence included on the list of probable periodontal pathogens *E. corrodens*, enteric rods, *Pseudomonas* species, *Selenomonas* species and *Staphylococcus* species. This report received general acceptance by the periodontal community and is still regarded as valid.

Even if there are no sufficient microbiological evidences that could help us in distinguishing the different forms of periodontitis, it is clear that:

- The chronic and aggressive forms of periodontitis are not mono-infections.
- Some microbiota are more important than others as etiological agents of periodontitis.

For these reasons, it appears clear that the microbial testing of sub-gingival plaque could be a valid support for a correct diagnosis of periodontitis. The anaerobic culture test is the most sophisticated technique to

analyse the composition of sub-gingival plaque. All cultivable microbial species in the sub-gingival sample can be detected, and proportions of the various pathogens can be established. Anaerobic culture testing allows the antimicrobial susceptibility testing of periodontal pathogens. Anaerobic culture testing is advised especially in the case of refractory periodontitis, atypical forms of pathogens or periodontitis, peri-implantitis and immunocompromised patients. In routine cases, a DNA-based chairside test (semi-quantitative polymerase chain reaction (PCR)) is indicated. Bacteria do not need to be viable; consequently, time is not an issue with the present test. The number of target bacteria is determined semi-quantitatively (0 to +++).

CSTs for bacteria detection provide information about the presence and relative importance of putative pathogens.

The periodontist has to follow the following steps in order to perform a correct DNA-based chairside test (semi-quantitative PCR) for bacterial plaque analysis:

1, Patient Date Of Birth: 00/00/0000 Gender: Male		Sample Information Accession: 00000000 Specimen: Oral Rinse Collected: 00/00/0000		Received: 00/00/0000 00:00 Reported: 00/00/0000 00:00 Printed: 00/00/0000 00:00	
Result: POSITIVE					
Results: IL-1A (+4845) Genotype G/T IL-1B (+3954) Genotype C/T					
Interpretation: The results of the PST test indicate that your patient is POSITIVE and has an increased risk for more severe periodontal disease due to the genetic variations examined in this test. PST-positive patients may require more aggressive treatment.					
Comments: <ul style="list-style-type: none">• Significance: This individual has the "PST-positive" genotype and is therefore at a 3-7 fold increased risk for severe periodontal disease. The PST composite genotype is based on the combination of the results for the IL-1A and IL-1B genes. Any combination that includes the presence of a "T" at both IL-1A (+4845) and IL-1B (+3954) is defined as PST-positive and predisposes an individual to more severe periodontal disease which may require more aggressive treatment.• Risk: Prevalence of the PST-positive genotype ranges from 30 to 40% in Caucasian populations. This frequency may be different in other ethnic groups. It is important to note that whenever the PST-positive genotype is present, it is associated with an increased susceptibility to periodontal disease and overproduction of IL-1, a cytokine that amplifies inflammation.• Consider: The PST test assesses one of several risk factors that should be included in an overall evaluation of periodontal disease. Specific bacteria are associated with the initiation of the disease, and additional risk factors including genetic susceptibility, smoking, diabetes, and oral hygiene have an amplifying effect on periodontal disease progression.					
<small>Methodology: Genomic DNA is extracted and tested for two Interleukin-1 polymorphisms. These polymorphisms are tested via polymerase chain reaction (PCR), followed by single base extension detection.</small>					
<small>Disclaimer: 1. OraDNA is not liable for any outcomes arising from clinician's treatment protocols and decisions. Dentists should consult with a periodontist or patient's physician when infections are advanced or as indicated by patient's medical condition. 2. OraDNA is not responsible for inaccurate test results due to poor sample collection. 3. This test was developed and its performance characteristics determined by Interleukin Genetics Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.</small>					

Figure 34 PST-positive genotype test interleukin-1A (+4845) and interleukin-1B (+3954). Several studies encourage the routine application of such tests to assess periodontal risk in a single patient.

- Meticulous removal of supra-gingival plaque.
- Sampling of sub-gingival plaque by the insertion of sterile paper points into the deepest pockets in each quadrant.
- Sending samples to a specialised laboratory.

The specialised laboratory will perform the DNA examination and identification of bacterial species. The number of target bacteria is determined semi-quantitatively (0 to +++) (Figure 35). Since optimal plaque control by the patient is of paramount importance for a favourable clinical and microbiologic response to therapy, microbiological analysis laboratory results should be discussed with patients in order to reinforce their compliance. Patients have to be placed on an individually tailored maintenance care programme, including the instruction of oral

hygiene, in order to obtain optimal plaque control and continuous evaluation of the occurrence of disease progression.

Fourth and fifth diagnostic levels: host response factors and tissue breakdown-derived products At present, well-studied molecules associated with host response factors and with derived tissue destruction mediators have been proposed as diagnostic biomarkers for periodontitis [102]. Many dental associations, such as the American Dental Association (ADA), recognise the importance of continued research on oral fluid diagnostics and welcome the development of rapid point-of-care tests that provide accurate measurements of clinically validated biomarkers. The ADA council 'encourages dentists to take leadership roles in integrating the tests




Figure 35 Consecutive steps to perform a correct DNA-based chairside test (semi-quantitative PCR) for bacterial plaque analysis.

Clinical diagnosis (chronic periodontitis or aggressive periodontitis), cigarette smoking, systemic pathologies and antibiotic consumption are the initial information requested. Then, a meticulous removal of supra-gingival plaque has to be performed. After that (see the figure clockwise), periodontal charting detects four different sites showing the deepest probing pocket depth whose values were reported on a DNA-PCR form. Clinical attachment level measures of the selected sites are also requested. In the present case, pyorrhea was present (blue arrow). Samples of sub-gingival plaque are carried out by the insertion of sterile paper points into the deepest pockets in each quadrant. Paper points are then stored into a vial and the samples sent to a specialised laboratory to perform the DNA examination and identification of bacterial species, together with the DNA-PCR form. The number of target bacteria is determined semi-quantitatively (0 to +++) and sent to the periodontist together with the diagnosis and therapy advice. Results are useful for the periodontist who will have a picture of a single patient's microbiological infection and for the patients in order to reinforce their compliance. Finally, the periodontist, having considered the species found, should propose an individually tailored maintenance care programme to a single patient.

and related technologies into clinical practice, consistent with the best available scientific evidence' [70].

We are going to discuss inflammatory/immunological reaction and sub-clinical tissue destruction in the same section since they:

1. Happen approximately at the same time.
2. Share the same modality of non-invasive sample collection.
3. Release biomarkers which can be detected in the same diagnostic medium (oral fluid, gingival crevicular fluid)

Oral fluid (whole saliva) as a diagnostic tool Probably the simplest organic diagnostic tool is oral fluid, a watery substance with multiple functions. Oral fluid or whole saliva is composed of 99.5% water, while the other 0.5% consists of antibacterial compounds. The advantages of using oral fluid as a diagnostic medium for a rapid

point-of-care testing include non-invasive sample collection, simplicity of access and acceptance by patients. Oral fluid (also called as *whole saliva*) is the fluid obtained from the mouth by expectoration. It includes glandular-duct saliva and gingival crevicular fluid:

1. Glandular-duct saliva: saliva secreted by the parotid, sub-mandibular, sub-lingual and minor salivary glands (2,000 ml/24 h) is obtained directly from the glandular ducts with specially designed collectors. Glandular-duct saliva contains predominantly secretory IgA.
2. Gingival crevicular fluid (GCF) is an exudate flushing from the gingival sulcus (0.5 to 2.5 ml/24 h). GCF is a versatile and non-invasive means to sample the biomarkers of inflammation and bone resorption in the oral cavity. GCF represents serum components overlaid with products from local physiologic or

pathologic phenomena. In particular, pathologic phenomena such as connective tissue destruction and bone loss may have a diagnostic value [103,104]. Whilst gingival crevicular fluid is the most appropriate diagnostic medium to use in analyses, it appears clear that the use of whole saliva is more practical even if reactants need to be highly sensitive since biomarkers are more diluted [105,106].

Salivary biomarkers for periodontal disease

Recently, the entire human salivary proteome was reported by a consortium of three research groups [107], and this revealed that 1,166 proteins are present in human saliva [108]. Over 65 GCF components have been examined as possible markers for the progression of periodontitis (for a complete review, see [109]). These components fall into three general categories: (1) host-derived enzymes and their inhibitors, (2) inflammatory mediators and host response modifiers and (3) tissue breakdown products. We have searched the literature for more promising components of gingival crevicular fluid in regard to potential diagnostic value for periodontitis (Table 5) (for a complete review, see [110]).

Alkaline phosphatase (host-derived enzyme)

Alkaline phosphatase is an enzyme produced principally by neutrophils and then by fibroblasts, osteoblasts, osteoclasts and several bacteria. It plays a role in the physiological turnover of the periodontal ligament, root cement and alveolar bone. The amount of alkaline phosphatase in gingival crevicular fluid samples appears higher in the active sites than in the inactive sites. Moreover, elevated alkaline phosphatase levels preceded attachment loss, while no clinical parameters were yet discriminatory [111].

Table 5 Most promising salivary biomarkers for the diagnosis of periodontal disease

Salivary biomarkers	Components
Host-derived enzymes	Alkaline phosphatase
	Beta-glucuronidase
	Cathepsin B
	MMP-8 (collagenase-2)
	MMP-9 (gelatinase)
	Dipeptidyl peptidases II and IV
Host response modifiers	Elastase
	RANKL
	OPG
Tissue breakdown products	RANK
	1-CTP
	C-4-S

Beta-glucuronidase (host-derived enzyme)

Beta-glucuronidase is a lysosomal enzyme that could be thought as an indicator of periodontal disease activity. Lamster et al. [112] showed a predictive value for beta-glucuronidase in relation to clinical attachment loss. Nakashima et al. [111] reported that beta-glucuronidase was significantly higher in active vs. inactive sites.

Cathepsin B (host-derived enzyme)

Cathepsin B is an enzyme active in proteolysis. Macrophages are the cellular source of cathepsin B in gingival crevicular fluid [113]. Cathepsin B levels (1) have been found to be increased in periodontitis but not in gingivitis, (2) were higher in rapid loss sites than in paired control sites and (3) appeared reduced after periodontal treatment [114-116].

MMP-8 (collagenase-2) (host-derived enzyme)

MMP-8 in gingival crevicular fluid has latent and active forms. The latent enzyme may be present in gingivitis and the active form in periodontitis. MMP-8 appears 18-fold higher in progressing periodontitis vs. stable periodontitis [117]. Mancini et al. proposed the use of MMP-8 levels in gingival crevicular fluid as a test for active periodontal destruction [118].

MMP-9 (gelatinase) (host-derived enzyme)

MMP-9 appears elevated in subjects affected by advanced periodontitis associated with red complex anaerobic periodontal pathogens (e.g. *P. gingivalis* and *T. denticola*) [119]. Samples from patients with recurrent attachment loss showed a twofold increase of mean active MMP-9, and these levels decreased significantly following adjunctive metronidazole therapy [120].

Dipeptidyl peptidases II and IV (host-derived enzyme)

Neutrophils, lymphocytes, macrophages and fibroblasts are the main sources of dipeptidyl peptidases II and IV. Their main function lies in the activation of the pro-forms of cytokines and enzymes and in the degradation of collagen tissue. Higher levels of both enzymes in sites with rapid and gradual attachment loss were reported with respect to sites without attachment loss [121].

Elastase (host-derived enzyme)

Elastase is a proteinase released from the azurophilic granules of neutrophils and from macrophages (also called MMP-12). Elastase has been recorded in GCF from periodontal patients at elevated levels and reduced after periodontal treatment. Many authors [122-124] observed higher elastase levels in sites demonstrating progressive attachment loss in comparison with inactive sites.

RANKL/OPG/RANK system (host response modifiers)

The RANKL/OPG/RANK system can be detected in the gingival tissue, GCF and saliva. In the course of periodontitis, RANKL is secreted by osteoblasts, fibroblasts, bone marrow stromal cells and activated T and B cells. Under physiological condition, RANKL produced by osteoblasts binds to RANK on the surface of pre-osteoclasts. RANKL is up-regulated by osteotropic factors such as OPG. RANKL is increased whereas OPG is decreased in periodontitis compared to healthy gingiva or gingivitis [125].

1-CTP (tissue breakdown products)

Pyridinoline cross-links represent a class of collagen-degrading molecules that include pyridinoline, deoxypyridinoline, N-telopeptides and C-telopeptides. The role of pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (1-CTP) levels in gingival crevicular fluid as a diagnostic marker of periodontal disease activity has been investigated by several studies. High levels of 1-CTP were strongly correlated with clinical parameters and putative periodontal pathogens. Results showed that 1-CTP appeared as a good predictor of future alveolar bone and attachment loss and demonstrated significant reductions after periodontal therapy [126].

C-4-S (tissue breakdown products)

Chondroitin-4-sulphate (C-4-S) is the most common glycosaminoglycan in untreated chronic periodontitis sites, as shown in both animal and human studies. Elevated glycosaminoglycan concentrations were also found in aggressive periodontal diseases, and associations have been made with periodontal pathogens such as *P. gingivalis* [126]. A statistically significant correlation between the GCF content of C-4-S, a bone-specific glycosaminoglycan, and PPD and CAL was reported [127].

Conclusions

Oral fluid is the mirror of periodontal health. It is a medium for clinically relevant information since it contains biomarkers specific for periodontal diseases. Although the periodontal diagnostic value of oral fluid has been recognised for some time, most scientific papers in the recent past have failed to support consistent aids to the clinician in periodontal diagnosis and therapy. Advances in microfluidics technology are revolutionising molecular biology procedures for enzymatic analysis, DNA analysis and proteomics. The evolution of microfluidics, *digital microfluidics*, appears promising for future application to diagnose periodontal diseases and to prognosticate periodontal treatment.

Lab-on-a-chip technology may soon become an important part of efforts to improve worldwide periodontal health [128]. In developed nations, the most highly



Figure 36 A 24-year-old patient from Nigeria suffering from generalised aggressive periodontitis. Periodontal diagnosis was effected in Naples (Italy) when the disease had already destroyed up to 80% of the periodontal supporting bone.

valued qualities for portable, easy-to-use diagnostic tools include speed, sensitivity and specificity; while in the underserved communities, resource-poor areas and poor countries, the goal of researchers is to create microfluidic chips that will allow healthcare providers in poorly equipped hospitals [129] (Figures 36 and 37).

The use of LOC devices for periodontal inspection will involve less education than current diagnostic procedures and allow patients to be screened for periodontal disease in settings other than the periodontist practice, such as at general practitioners, general dentists or dental hygienists [130].

All these benefits make the lab-on-a-chip technology ideal for predictive, preventive, personalised and participatory periodontology. The 5Ps represents with no doubt the future of our profession. Personalised therapy with tailored respect to the particular medical reality of the specific stratified patient will be the ultimate target




Figure 37 A panoramic X-ray of the same patient. An advanced generalised destruction of the supporting bone tissue is evident. One of the most important topics in periodontal diagnosis in the next future will be to create microfluidic chips allowing healthcare providers in poorly equipped hospitals and areas of the world.

to be realized by the 5Ps approach. A long distance has to be covered to reach the above targets, but the pathway has already been clearly outlined: it is 'time for new guidelines in advanced healthcare' in dentistry too [131].

Consent

Written informed consent was obtained from the patients for the publication of this report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

CC and SM conceived the present paper and participated in its draft. Both authors read and approved the final manuscript.

Authors' information

CC is a researcher and professor at the University of Naples "FEDERICO II". SM is a full professor and the Chairman of the Degree Course in Dentistry at the University of Naples "FEDERICO II".

Acknowledgements

The authors wish to thank the International Diabetes Federation for giving permission to reproduce Figure 19 and Prof. Dr. Christoph A. Ramseier, Department of Periodontology, University of Berne, Switzerland for giving permission to reproduce Figures 22 and 28. The authors thank Dr. Pierpaolo 'Pirre' Ballone for the drawings, the dental student Michele Colamaio who helped in the digital organisation of the figures and Dr. Claudia Meoli who revised the text.

Received: 19 March 2013 Accepted: 6 May 2013

Published: 14 June 2013

References

1. European Association for Predictive, Preventive and Personalised Medicine - EPMA. [<http://www.epmanet.eu>].
2. Golubnitschaja O, Costigliola V, EPMA: General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. *EPMA J* 2012, **3**:14.
3. Lindhe J, Lang NP, Karring T: The anatomy of periodontal tissue. In *Clinical Periodontology and Implant Dentistry. Volume 1*. 5th edition. Edited by Lindhe J, Karring T, Araujo M. Copenhagen: Blackwell Munksgaard; 2008:3-48.
4. Armitage GC: Development of a classification system for periodontal diseases and conditions. *Ann Periodontol* 1999, **4**:1-6.
5. Socransky SS: Microbiology of periodontal disease - present status and future considerations. *J Periodontol* 1977, **48**(9):497-504.
6. Sweeney EA, Alcoforado GA, Nyman S, Slots J: Prevalence and microbiology of localized prepubertal periodontitis. *Oral Microbiol Immunol* 1987, **2**(2):65-70.
7. Bimstein E, Treasure ET, Williams SM, Dever JG: Alveolar bone loss in 5-year-old New Zealand children: its prevalence and relationship to caries prevalence, socio-economic status and ethnic origin. *J Clin Periodontol* 1994, **21**(7):447-450.
8. Sjödin B, Matsson L: Marginal bone loss in the primary dentition. A survey of 7-9-year-old children in Sweden. *J Clin Periodontol* 1994, **21**(5):313-319.
9. Lang N, Bartold PM, Cullinan M, Jeffcoat M, Mombelli A, Murakami S, Page R, Papapanou P, Tonetti M, Van Dyke T: Consensus report: aggressive periodontitis. *Ann Periodontol* 1999, **4**:53.
10. Tonetti MS, Mombelli A: Early-onset periodontitis. *Ann Periodontol* 1999, **4**(1):39-53.
11. Lindhe J, Lang NP, Karring T: Aggressive periodontitis. In *Clinical Periodontology and Implant Dentistry. Volume 2*. 5th edition. Edited by Tonetti M, Mombelli A. Copenhagen: Blackwell Munksgaard; 2008:429-449.
12. Loevy HT: Genetic aspects of periodontal disease. *Quintessence Int* 1976, **5**:1-4.
13. Kinane DF, Hart TC: Genes and gene polymorphisms associated with periodontal disease. *Crit Rev Oral Biol Med* 2003, **14**:430-449.
14. Loos BG, John RP, Laine ML: Identification of genetic risk factors for periodontitis and possible mechanisms of action. *J Clin Periodontol* 2005, **32**(Suppl 6):159-179.
15. Keijser BJ, Zaura E, Huse SM, van der Vossen JM, Schuren FH, Montijn RC, Ten Cate JM, Crielaard W: Pyrosequencing analysis of the oral microflora of healthy adults. *J Dent Res* 2008, **87**:1016-1020.
16. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL Jr: Microbial complexes in subgingival plaque. *J Clin Periodontol* 1998, **25**:134-144.
17. Slots J, Slots H: Bacterial and viral pathogens in saliva: disease relationship and infectious risk. *Periodontol* 2000 2011, **55**:48-69.
18. Zambon JJ, Christersson LA, Slots J: Actinobacillus actinomycetemcomitans in human periodontal disease. Prevalence in patient groups and distribution of biotypes and serotypes within families. *J Periodontol* 1983, **54**:707-711.
19. Asikainen S, Chen C, Slots J: Likelihood of transmitting *Actinobacillus actinomycetemcomitans* and *Porphyromonas gingivalis* in families with periodontitis. *Oral Microbiol Immunol* 1996, **11**:387-394.
20. Altman LC, Baker C, Fleckman P, Luchtel D, Oda D: Neutrophil mediated damage to human gingival epithelial cells. *J Periodontol Res* 1992, **27**:70-79.
21. Weiss SJ: Tissue destruction by neutrophils. *N Engl J Med* 1989, **320**:365-376.
22. Dewhirst FE, Ago JM, Peros W, Stashenko P: Synergism between parathyroid hormone and interleukin-1 in stimulating bone resorption in organ culture. *J Bone Miner Res* 1987, **2**:127-134.
23. Beutler B, Cerami A: Cachectin and tumour necrosis factor as two sides of the same biological coin. *Nature* 1986, **320**:584-588.
24. Cox SW, Eley BM: Detection of cathepsin B- and L-, elastase-, trypsin-, and dipeptidyl peptidase IV-like activities in crevicular fluid from gingivitis and periodontitis patients with peptidyl derivatives of 7-amino-4-trifluoromethyl coumarin. *J Period Res* 1989, **24**:351-353.
25. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL: The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. *J Cell Biol* 1999, **145**(3):527-538.
26. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yanai K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. *Endocrinology* 1998, **139**(3):1329-1337.
27. Stabholz A, Stabholz A, Soskolne AW, Shapira L: Genetic and environmental risk factors for chronic periodontitis and aggressive periodontitis. *Periodontol* 2000 2010, **53**:138-153.
28. International Diabetes Federation. [<http://www.idf.org/diabetesatlas/5c/update> 2012].
29. Hanes PJ, Krishna R: Characteristics of inflammation common to both diabetes and periodontitis: are predictive diagnosis and targeted preventive measures possible? *EPMA J* 2010, **1**:101-116.
30. Tervonen T, Oliver RC: Long-term control of diabetes mellitus and periodontitis. *J Clin Periodontol* 1993, **20**:431-435.
31. Cianciola LJ, Park BH, Bruck E, Mosovich L, Genco RJ: Prevalence of periodontal disease in insulin-dependent diabetes mellitus (juvenile diabetes). *J Am Dent Assoc* 1982, **104**:653-660.
32. Løe H: Periodontal disease. The sixth complication of diabetes mellitus. *Diabetes Care* 1993, **16**:329-334.
33. Grossi SG, Zambon JJ, Ho AW, Koch G, Dunford RG, Machtei EE, Norderyd OM, Genco RJ: Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. *J Periodontol* 1994, **65**:260-267.
34. Grossi SG, Genco RJ: Periodontal disease and diabetes mellitus: a two-way relationship. *Ann Periodontol* 1998, **3**:51-61.
35. D'aiuto F, Parkar M, Andreou G, Suvan J, Brett P, Ready D, Tonetti MS: Periodontitis and systemic inflammation: control of the local infections is associated with a reduction of serum inflammatory markers. *J Dent Res* 2004, **83**:156-160.
36. Iwamoto Y, Nishimura F, Nakagawa M, Sugimoto H, Shikata K, Makino H, Fukuda T, Tsuji T, Iwamoto M, Murayama Y: The effect of antimicrobial periodontal treatment on circulating tumor necrosis factor-alpha and glycated hemoglobin level in patients with type 2 diabetes. *J Periodontol* 2001, **72**(6):774-778.
37. Nishimura F, Murayama Y: Periodontal inflammation and insulin resistance-lessons from obesity. *J Dent Res* 2001, **80**:1690-1694.

38. Promsudthi A, Pimapansri S, Deerochanawong C, Kanchanasavita W: **The effect of periodontal therapy on uncontrolled type 2 diabetes mellitus in older subjects.** *Oral Dis* 2005, **11**:293–298.
39. Aldridge JP, Lester V, Watts TL, Collins A, Viberti G, Wilson RF: **Single-blind studies of the effects of improved periodontal health on metabolic control in type 1 diabetes mellitus.** *J Clin Periodontol* 1995, **22**:271–275.
40. Christgau M, Palitzsch KD, Schmalz G, Kreiner U, Frenzel S: **Healing response to non-surgical periodontal therapy in patients with diabetes mellitus: clinical, microbiological, and immunologic results.** *J Clin Periodontol* 1998, **25**:112–124.
41. Darré L, Vergnes JN, Gourdy P, Sixou M: **Efficacy of periodontal treatment on glycaemic control in diabetic patients: a meta-analysis of interventional studies.** *Diabetes Metab* 2008, **34**:497–506.
42. Simpson TC, Needleman I, Wild SH, Moles DR, Mills EJ: **Treatment of periodontal disease for glycaemic control in people with diabetes.** *Cochrane Database Syst Rev* 2010, **12**(5), CD004714.
43. Tonetti MS: **Cigarette smoking and periodontal diseases: etiology and management of disease.** *Ann Periodontol* 1998, **3**:88–101.
44. Calsina G, Ramon JM, Echeverria JJ: **Effects of smoking on periodontal tissues.** *J Clin Periodontol* 2002, **29**:771–776.
45. Machuca G, Rosales I, Lacalle JR, Machuca C, Bullon P: **Effect of cigarette smoking on periodontal status of healthy young adults.** *J Periodontol* 2000, **71**:73–78.
46. Palmer RM, Wilson RF, Hasan AS, Scott DA: **Mechanisms of action of environmental factors – tobacco smoking.** *J Clin Periodontol* 2005, **32** (Suppl 6):180–195.
47. Rieder C, Joss A, Lang NP: **Influence of compliance and smoking habits on the outcomes of supportive periodontal therapy (SPT) in a private practice.** *Oral Health Prev Dent* 2004, **2**:89–94.
48. Ritchie CS: **Obesity and periodontal disease.** *Periodontol 2000* 2007, **44**:154–163.
49. Kershaw EE, Flier JS: **Adipose tissue as an endocrine organ.** *J Clin Endocrinol Metab* 2004, **89**:2548–2556.
50. Saito T, Shimazaki Y, Sakamoto M: **Obesity and periodontitis.** *N Engl J Med* 1998, **339**:482–483.
51. Al-Zahrani MS, Bissada NF, Borawski EA: **Obesity and periodontal disease in young, middle-aged, and older adults.** *J Periodontol* 2003, **74**:610–615.
52. Linden G, Patterson C, Evans A, Kee F: **Obesity and periodontitis in 60-70-year-old men.** *J Clin Periodontol* 2007, **34**:461–466.
53. Genco RJ, Grossi SG, Ho A, Nishimura F, Murayama Y: **A proposed model linking inflammation to obesity, diabetes, and periodontal infections.** *J Periodontol* 2005, **76**:2075–2084.
54. Al-Zahrani MS, Borawski EA, Bissada NF: **Increased physical activity reduces prevalence of periodontitis.** *J Dent* 2005, **33**:703–710.
55. Al-Zahrani MS, Borawski EA, Bissada NF: **Periodontitis and three health-enhancing behaviors: maintaining normal weight, engaging in recommended level of exercise, and consuming a high-quality diet.** *J Periodontol* 2005, **76**:1362–1366.
56. Kiecolt-Glaser JK, Ricker D, George J, Messick G, Speicher CE, Garner W, Glaser R: **Urinary cortisol levels, cellular immunocompetency, and loneliness in psychiatric inpatients.** *Psychosom Med* 1984, **46**:15–23.
57. Boyapati L, Wang HL: **The role of stress in periodontal disease and wound healing.** *Periodontol 2000* 2007, **44**:195–210.
58. Peruzzo DC, Benatti BB, Ambrosano GM, Nogueira-Filho GR, Sallum EA, Casati MZ, Nociti FH Jr: **A systematic review of stress and psychological factors as possible risk factors for periodontal disease.** *J Periodontol* 2007, **78**:1491–1504.
59. Wactawski-Wende J: **Periodontal diseases and osteoporosis: association and mechanisms.** *Ann Periodontol* 2001, **6**:197–208.
60. Von Wowern N, Klausen B, Olgaard K: **Steroid-induced mandibular bone loss in relation to marginal periodontal changes.** *J Clin Periodontol* 1992, **19**:182–186.
61. Yoshihara A, Seida Y, Hanada N, Miyazaki H: **A longitudinal study of the relationship between periodontal disease and bone mineral density in community-dwelling older adults.** *J Clin Periodontol* 2004, **31**:680–684.
62. Ramseier CA: **Periodontal chart.** [<http://www.periodontalchart-online.com/uk/index.asp>].
63. Lang NP, Adler R, Joss A, Nyman S: **Absence of bleeding on probing. An indicator of periodontal stability.** *J Clin Periodontol* 1990, **17**:714–721.
64. Lang NP, Joss A, Tonetti MS: **Monitoring disease during supportive periodontal treatment by bleeding on probing.** *Periodontol 2000* 1996, **12**:44–48.
65. Joss A, Adler R, Lang NP: **Bleeding on probing. A parameter for monitoring periodontal conditions in clinical practice.** *J Clin Periodontol* 1994, **21**:402–408.
66. Lang NP, Tonetti MS: **Periodontal risk assessment (PRA) for patients in supportive periodontal therapy (SPT).** *Oral Health Prev Dent* 2003, **1**:7–16.
67. Ramseier CA: **Periodontal risk assessment.** [<http://www.perio-tools.com/prae/en/index.asp>].
68. Chapple ILC: **Periodontal diagnosis and treatment – where does the future lie?** *Periodontol 2000* 2009, **51**:9–24.
69. Point of Care Diagnostic Testing World Markets. TriMark Publications, LLC; 2012.
70. American Dental Association: **Statement on oral fluid diagnostics.** [<http://www.ada.org/1890.aspx>].
71. Albandar JM, Brunelle JA, Kingman A: **Destructive periodontal disease in adults 30 years of age and older in the United States, 1988–1994.** *J Periodontol* 1999, **70**:13–29.
72. Ashton R, Padala C, Kane RS: **Microfluidic separation of DNA.** *Curr Opin Biotechnol* 2003, **14**:497–504.
73. Paegel BM, Blazej R, Mathies RA: **Microfluidic devices for DNA sequencing: sample preparation and electrophoretic analysis.** *Curr Opin Biotechnol* 2003, **14**:42–50.
74. Lion N, Rohner TC, Dayon L, Arnaud IL, Damoc E, Youhnovski N, Wu ZY, Roussel C, Josserand J, Jensen H, Rossier JS, Przybylski M, Girault HH: **Microfluidic systems in proteomics.** *Electrophoresis* 2003, **24**:3533–3562.
75. Huh D, Gu W, Kamotani Y, Grotberg JB, Takayama S: **Microfluidics for flow cytometric analysis of cells and particles.** *Physiol Meas* 2005, **26**:R73–R98.
76. Srinivasan V, Pamula VK, Fair RB: **An integrated digital microfluidic lab-on-a-chip for clinical diagnostics on human physiological fluids.** *Lab Chip* 2004, **4**:310–315.
77. Tangerman A: **Halitosis in medicine: a review.** *Int Dent J* 2002, **52**:201–206.
78. Golberg S, Kozlovsky A, Gordon D: **Cadaverine as a putative component of oral malodor.** *J Dent Res* 1994, **73**:1168–1172.
79. Ratcliff PA, Johnson PW: **The relationship between oral malodor, gingivitis, and periodontitis.** *J Periodontol* 1999, **70**:485–489.
80. Rosenberg M: **Clinical assessment of bad breath: current concepts.** *J Am Dent Assoc* 1996, **127**:475–482.
81. Persson S, Edlund MB, Claesson R, Carlsson J, Persson S, Edlund MB, Claesson R, Carlsson J: **The formation of hydrogen sulfide and methyl mercaptan by oral bacteria.** *Oral Microbiol Immunol* 1990, **5**:195–201.
82. Morita M, Wang HL: **Relationship of sulcular sulfide level to severity of periodontal disease and BANA test.** *J Periodontol* 2001, **72**:74–78.
83. Rosenberg M, Leib E: **Experiences of an Israeli malodor clinic.** In *Bad Breath: Research Perspectives*. Edited by Rosenberg M. Tel Aviv: Ramot Publishing, Tel Aviv University; 1995:137–148.
84. Hanada M, Koda H, Onaga K, Tanaka K, Okabayashi T, Itoh T, Miyazaki H: **Portable oral malodor analyzer using highly sensitive In₂O₃ gas sensor combined with a simple gas chromatography.** *Anal Chim Acta* 2003, **475**:27–35.
85. Salako NO, Philip L: **Comparison of the use of the Halimeter and the Oral Chroma™ in the assessment of the ability of common cultivable oral anaerobic bacteria to produce malodorous volatile sulfur compounds from cysteine and methionine.** *Med Princ Pract* 2011, **20**:75–79.
86. Hatcher DC, Hatcher DC: **Operational principles for cone-beam computed tomography.** *J Am Dent Assoc* 2010, **141**:35–65.
87. Nikolopoulos GK, Dimou NL, Hamodrakas SJ, Bagos PG: **Cytokine gene polymorphisms in periodontal disease: a meta-analysis of 53 studies including 4178 cases and 4590 controls.** *J Clin Periodontol* 2008, **35**:754–767.
88. Kobayashi T, Yamamoto K, Sugita N, van der Pol WL, Yasuda K, Kaneko S, van de Winkel JG, Yoshie H: **The Fc gamma receptor genotype as a severity factor for chronic periodontitis in Japanese patients.** *J Periodontol* 2001, **72**:1324–1331.
89. Loos BG, De Straat FG L-V, Van de Winkel JG, Van der Velden U: **Fc gamma receptor polymorphisms in relation to periodontitis.** *J Clin Periodontol* 2003, **30**:595–602.
90. March CJ, Mosley B, Larsen A, Cerretti DP, Braedt G, Price V, Gillis S, Henney CS, Kronheim SR, Grabstein K: **Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs.** *Nature* 1985, **315**:641–647.
91. Komman KS, Crane A, Wang HY, Di Giovine FS, Newman MG, Pirk FW, Wilson TG Jr, Higginbottom FL, Duff GW: **The interleukin-1 genotype as a severity factor in adult periodontal disease.** *J Clin Periodontol* 1997, **24**:72–77.
92. Gore EA, Sanders JJ, Pandey JP, Palesch Y, Galbraith GM: **Interleukin-1beta + 3953 allele 2: association with disease status in adult periodontitis.** *J Clin Periodontol* 1998, **25**:781–785.

93. Taylor JJ, Preshaw PM, Donaldson PT: Cytokine gene polymorphism and immunoregulation in periodontal disease. *Periodontol 2000* 2004, **35**:158–182.
94. Yoshie H, Kobayashi T, Tai H, Galicia JC: The role of genetic polymorphisms in periodontitis. *Periodontol 2000* 2007, **43**:102–132.
95. Papanou PN, Neiderud AM, Sandros J, Dahlén G: Interleukin-1 gene polymorphism and periodontal status. A case-control study. *J Clin Periodontol* 2001, **28**:389–396.
96. Cattabriga M, Rotundo R, Muzzi L, Nieri M, Verrocchi G, Cairo F, Pini PG: Retrospective evaluation of the influence of the interleukin-1 genotype on radiographic bone levels in treated periodontal patients over 10 years. *J Periodontol* 2001, **72**:767–773.
97. Greenstein G, Hart TC: Clinical utility of a genetic susceptibility test for severe chronic periodontitis: a critical evaluation. *J Am Dent Assoc* 2002, **133**:452–459.
98. Haffajee AD, Socransky SS: Microbial etiological agents of destructive periodontal diseases. *Periodontol* 1994, **5**:78–111.
99. Genco R, Kornman K, Williams R, Offenbacher S, Zambon JJ, Listgarten M, Michalowicz B, Page R, Schenkein H, Slots J, Socransky S, Van Dyke T: Consensus report periodontal diseases: pathogenesis and microbial factors. *Ann Periodontol* 1996, **1**:926–932.
100. Nørskov-Lauritsen N, Kilian M: Reclassification of *Actinobacillus actinomycetemcomitans*, *Haemophilus aphrophilus*, *Haemophilus paraprophyllus* and *Haemophilus segnis* as *Aggregatibacter actinomycetemcomitans* gen. nov., comb. nov., *Aggregatibacter aphrophilus* comb. nov. and *Aggregatibacter segnis* comb. nov., and emended description of *Aggregatibacter aphrophilus* to include V factor-dependent and V factor-independent isolates. *Int J Syst Evol Microbiol* 2006, **56**:2135–2146.
101. Sakamoto M, Suzuki M, Umeda M, Ishikawa I, Benno Y: Reclassification of *Bacteroides forsythus* as *Tannerella forsythensis* corrig., gen. nov., comb. nov. *Int J Syst Evol Microbiol* 2002, **52**:841–849.
102. Taba M Jr, Kinney J, Kim AS, Giannobile WW: Diagnostic biomarkers for oral and periodontal diseases. *Dent Clin North Am* 2005, **49**:551–571.
103. Lamster IB: Evaluation of components of gingival crevicular fluid as diagnostic tests. *Ann Periodontol* 1997, **2**:123–137.
104. Sorsa T, Tjäderhane L, Kontinen YT, Lauhio A, Salo T, Lee HM, Golub LM, Brown DL, Mäntylä P: Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. *Ann Med* 2006, **38**:306–321.
105. Chapple ILC: Periodontal disease diagnosis: current status and future developments. *J Dent* 1997, **25**:3–15.
106. Chapple ILC, Matthews JB, Thorpe GH, Glenwright HD, Smith JM, Saxby MS: A new ultrasensitive chemiluminescent assay for the site-specific quantification of alkaline phosphatase in gingival crevicular fluid. *J Periodontol Res* 1993, **28**:266–273.
107. Denny P, Hagen FK, Hardt M, Liao L, Yan W, Arellano M, Bassilian S, Bedi GS, Boontheung P, Cociorva D, Delahunty CM, Denny T, Dunsmore J, Faulk KF, Gilligan J, Gonzalez-Begne M, Halgand F, Hall SC, Han X, Henson B, Hewel J, Hu S, Jeffrey S, Jiang J, Loo JA, Ogorzalek Loo RR, Malamud D, Melvin JE, Miroshnichenko O, Navazesh M, et al: The proteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions. *J Proteome Res* 2008, **7**:1994–2006.
108. The Human Salivary Proteome Project. [http://www.skb.ucla.edu].
109. Armitage GC: Analysis of gingival crevice fluid and risk of progression of periodontitis. *Periodontol 2000* 2004, **34**:109–119.
110. Loos BG, Tjoa S: Host-derived diagnostic markers for periodontitis: do they exist in gingival crevice fluid? *Periodontol 2000* 2005, **39**:53–72.
111. Nakashima K, Giannopoulos C, Andersen E, Roehrich N, Brochut P, Dubrez B, Cimasoni G: A longitudinal study of various crevicular fluid components as markers of periodontal disease activity. *J Clin Periodontol* 1996, **23**:832–838.
112. Lamster IB, Holmes LG, Gross KB, Oshrain RL, Cohen DW, Rose LF, Peters LM, Pope MR: The relationship of beta-glucuronidase activity in crevicular fluid to probing attachment loss in patients with adult periodontitis. Findings from a multicenter study. *J Clin Periodontol* 1995, **22**:36–44.
113. Kennett CN, Cox SW, Eley BM: Investigations into the cellular contribution to host tissue proteases and inhibitors in gingival crevicular fluid. *J Clin Periodontol* 1997, **24**:424–431.
114. Eley BM, Cox SW: The relationship between gingival crevicular fluid cathepsin B activity and periodontal attachment loss in chronic periodontitis patients: a 2-year longitudinal study. *J Periodontol Res* 1996, **31**:381–392.
115. Chen HY, Cox SW, Eley BM: Cathepsin B, alpha2-macroglobulin and cystatin levels in gingival crevicular fluid from chronic periodontitis patients. *J Clin Periodontol* 1998, **25**:34–41.
116. Cox SW, Eley BM: Cathepsin B/L-, elastase-, trypsin-, trypsin- and dipeptidyl peptidase IV-like activities in gingival crevicular fluid. A comparison of levels before and after basic periodontal treatment of chronic periodontitis patients. *J Clin Periodontol* 1992, **19**:333–339.
117. Ramseier CA, Kinney JS, Herr AE, Braun T, Sugai JV, Shelburne CA, Rayburn LA, Tran HM, Singh AK, Giannobile WW: Identification of pathogen and host-response markers correlated with periodontal disease. *J Periodontol* 2009, **80**:436–446.
118. Mancini S, Romanelli R, Laschinger CA, Overall CM, Sodek J, McCulloch CA: Assessment of a novel screening test for neutrophil collagenase activity in the diagnosis of periodontal diseases. *J Periodontol* 1999, **70**:1292–1302.
119. Giannobile WW: Salivary diagnostics for periodontal diseases. *J Am Dent Assoc* 2012, **143**:65–115.
120. Teng YT, Sodek J, McCulloch CA: Gingival crevicular fluid gelatinase and its relationship to periodontal disease in human subjects. *J Periodontol Res* 1992, **27**:544–552.
121. Eley BM, Cox SW: Correlation between gingival crevicular fluid dipeptidyl peptidase II and IV activity and periodontal attachment loss. A 2-year longitudinal study in chronic periodontitis patients. *Oral Dis* 1995, **1**:201–213.
122. Jin L, Soder B, Corbet EF: Interleukin-8 and granulocyte elastase in gingival crevicular fluid in relation to periodontopathogens in untreated adult periodontitis. *J Periodontol* 2000, **71**:929–939.
123. Smith QT, Harriman L, Au GS, Stoltenberg JL, Osborn JB, Aeppli DM, Fischer G: Neutrophil elastase in crevicular fluid: comparison of a middle-aged general population with healthy and periodontitis groups. *J Clin Periodontol* 1995, **22**:935–941.
124. Palcanis KG, Larjava IK, Wells BR, Suggs KA, Landis JR, Chadwick DE, Jeffcoat MK: Elastase as an indicator of periodontal disease progression. *J Periodontol* 1992, **63**:237–242.
125. Belibasakis GN, Bostanci N: The RANKL-OPG system in clinical periodontology. *J Clin Periodontol* 2012, **39**:239–248.
126. Giannobile WW, Al-Shammari KF, Sarment DP: Matrix molecules and growth factors as indicators of periodontal disease activity. *Periodontol 2000* 2003, **31**:125–134.
127. Smith AJ, Addy M, Embery G: Gingival crevicular fluid glycosaminoglycan levels in patients with chronic adult periodontitis. *J Clin Periodontol* 1995, **22**:355–361.
128. Yager P, Edwards T, Elain F, Helton K, Nelson K, Tam MR, Weigl BH: Microfluidic diagnostic technologies for global public health. *Nature* 2006, **442**:412–418.
129. Giannobile WW, Beikler T, Kinney JS, Ramseier CA, Morelli T, Wong DT: Saliva as a diagnostic tool for periodontal disease: current state and future directions. *Periodontol 2000* 2009, **50**:52–64.
130. Christodoulides N, Floriano PN, Miller CS, Ebersole JL, Mohanty S, Dharshan P, Griffin M, Lennart A, Ballard KL, King CP Jr, Langub MC, Kryscio RJ, Thomas MV, McDevitt JT: Lab-on-a-chip methods for point-of-care measurements of salivary biomarkers of periodontitis. *Ann N Y Acad Sci* 2007, **1098**:411–428.
131. Golubnitschaja O: Time for new guidelines in advanced healthcare: the mission of The EPMA Journal to promote an integrative view in predictive, preventive and personalized medicine. *EPMA J* 2012, **3**:5.

doi:10.1186/1878-5085-4-16

Cite this article as: Cafiero and Matarasso: Predictive, preventive, personalised and participatory periodontology: 'the 5Ps age' has already started. *The EPMA Journal* 2013 **4**:16.